WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

NCT01266083 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Galinpepimut-S
BIOLOGICAL: GM-CSF
OTHER: Montanide

Sponsor

Sellas Life Sciences Group

Collaborators

[object Object]